Deep Sequencing for HIV-1 Resistance Assessment
Author Information
Author(s): Codoñer Francisco M., Pou Christian, Thielen Alexander, García Federico, Delgado Rafael, Dalmau David, Álvarez-Tejado Miguel, Ruiz Lidia, Clotet Bonaventura, Paredes Roger
Primary Institution: Institut de Recerca de la SIDA irsiCaixa-HIVACAT, Badalona, Spain
Hypothesis
Can deep HIV-1 sequencing provide additional clinically relevant information compared to population sequencing in heavily pre-treated HIV-1-infected subjects?
Conclusion
Deep sequencing improved the assessment of genotypic resistance to etravirine but did not consistently provide additional information on darunavir, tipranavir, or raltegravir susceptibility.
Supporting Evidence
- Deep sequencing detected all mutations found by population sequencing and identified additional resistance mutations in 6 out of 7 individuals.
- Additional genotypic information led to consistent decreases in predicted susceptibility to etravirine in 2 subjects.
- Deep sequencing provided limited additional genotypic information at baseline relative to population sequencing.
Takeaway
This study looked at how deep sequencing can help doctors understand HIV resistance better, especially in patients who have already tried many treatments.
Methodology
A proof-of-concept observational study comparing deep sequencing to population sequencing in HIV-1-infected individuals with previous treatment failures.
Potential Biases
Self-reported adherence may introduce bias in the results.
Limitations
The study had a small sample size and relied on self-reported treatment adherence.
Participant Demographics
The study included 7 individuals, 2 women, with a median age of 44 years and a median of 15 previous antiretroviral treatments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website